AC Immune SA

ACIUNASDAQ · USD
2.09USD-0.04 (-1.88%)
155

AC Immune SA (ACIU) Covered Calls

AC Immune SA trades in the Biotechnology industry with an IV Rank of 54.76%, average versus the past year. ACIU's highest covered call setup is the $5.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 134.74% out of the money with 189 days to expiration, a 137.09% return until expiration, and a 264.75% theoretical annualized return. Across the setups shown, annualized returns run from 73.44% to 264.75% at strikes between $2.50 and $5.00, with 98 to 189 days to expiration, as of Nov 13, 2026.

Read more

Running ACIU covered calls helps you generate income from AC Immune SA shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ACIU covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ACIU stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ACIU covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ACIU covered call is worth writing.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD).

2027-05-211895.00134.740.050.25292.00137.09264.75-2.35+0.23550.20
2027-02-19982.5017.370.050.4042.0019.7273.44-2.35+0.444030.35

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank54.76% Moderate
  • Market cap (M$)217
  • 52 weeks high-45.38%
  • 52 weeks low5.45%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$8.58
    310.53% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-04
  • P/E—
  • Future P/E6.58
  • EPS (ttm)-0.52
  • EPS growth next 5 years—

As of Nov 13, 2026